GovChime
Notice ID: 95bc90eff0454b96b2babcde72d0b955JustificationAwarded

6505--Contingency for Outsourcing Chemotherapy Compounding drug

Awarded on November 20, 2020. Full description on SAM.gov.

Awarded tounder 36C24221A0010 (source: SAM.gov award notice)• $0

Overview

Posted
November 23, 2020
Notice type
Justification
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
242-NETWORK CONTRACT OFFICE 02 (36C242)
Last updated
Sep 9, 2025
Award date
Nov 20, 2020
Award amount (SAM.gov award notice)
$0

Identifiers

Solicitation number
36C24221Q0219
Notice ID
95bc90eff0454b96b2babcde72d0b955

Description

VHAPM Part 813.106 Original Date: 08/30/17 Revision 02 Eff Date: 03/31/2020 Page 1 of 2 DEPARTMENT OF VETERANS AFFAIRS Justification for Single Source Awards IAW FAR 13.106-1 For Over Micro-Purchase Threshold but Not Exceeding the SAT ($250K) Acquisition Plan Action ID: 36C242-21-AP-0212 Contracting Activity: Department of Veterans Affairs, VISN 02, James J Peters VA Medical Center, 130 W. Kingsbridge Rd., Bronx, NY 10468 seeks to purchase pharmacy compounding chemotherapy drugs through on a non-competitive acquisition. Brief Description of Supplies/ Services required and the intended use/Estimated Amount: The request is to procure as a firm-fixed price, sole source, 5-year BPA agreement to a large business, compounded chemotherapy drugs delivered in the final form ready for administration to Veterans with oncology appointments. This includes patient specific orders, closed chemotherapy system (Equa-shield) pieces directly attached to the preparation, as well as appropriate IV lines and in-line filters. Currently, the campus drug hood and preparation room are out of service and this needs to be in place to cover on a case by case basis. The procurement will provide James J. Peters pharmacy department daily chemotherapy compounded drugs, pursuant to a valid order, signed by VA Oncologist for disease state treatment. The medication must be delivered on the day of scheduled treatment with enough beyond-use-dating to allow infusion of the chemotherapy during the day shift at infusion suite. The chemotherapy must be shipped in appropriate containers with enough ice packs or dry ice (or equivalent) as needed for refrigeration or freezing based on medication manufacturers guidelines. The final product must use Equa-shield closed system transfer devices and tubing required to allow for proper infusion. Period of Performance: Base Year: 11/20/2020-11/19/2021- Option Year 1: 11/20/2021-11/19/2022- Option Year 2: 11/20/2022-11/19/2023- Option Year 3: 11/20/2023-11/19/2024- Option Year 4: 11/20/2024-11/19/2025- Total Contract Value: Unique characteristics that limit availability to only one source, with the reason no other supplies or services can be used: is the only suitable 503A facility that has a few capabilities unique to them. Primarily they are capable of compounding personalized hazardous medications based off provider prescription with a wide formulary of agents. Additionally, they provide these medications connected to CSTDs (closed system transfer devices) that VA use within the facility and they maintain competency with and have receiving pieces to infuse patients. They have the capability to send these rapidly via FedEx with appropriate safety and cold chain storage requirements. Optum is capable of supporting VA patient load. They also fulfill all requirements for testing and quality assurance reporting. The 503A pharmacy completing this type of service must be USP< 797> and USP< 800> compliant, be a certified 503A pharmacy, maintain hood and room certification, and provide VA copies of all certifications, viable for particle testing, and competencies upon demand. The company is compliant in accordance with VHA Directive 1108.12. The high-quality pharmaceutical outsourcing (503A) can supply the following along with service required for the agency s needs: All products arrive Ready to Administer (admixed, spiked tubing, CSTD, labeled); all pharmacy have to do is administer the medication. One day turnaround time on all prescriptions. 15-point check system-done by pharmacists on each prescription. Unit cost, Inventory and supply savings-All drugs provided on a patient specific regimen. Eliminates drug-waste-No drug is wasted as a result of patient specific nature of compounding. Staff-Time-Elimination of non-reimbursable staff mixing time. USP<800>-all products mixed in USP<800>compliant environments. Description of market research conducted and results or statement why it was not conducted: Market research was conducted, which included consulting with a representative of the Original Pharmaceutical Manufacturer (OPM) trying to find potential suppliers of chemotherapy compound drugs, searching Veterans Information Pages (VIP), posting an intent to sole source on contract opportunities on 10/28/2020, searching Small Business Dynamics (SBA), searching VA NAC online pharmaceutical catalog, as well as communicating with peers throughout the VA network. This resulted in CO finding that even though there is a potential for one SDVOSB on VIP that could maybe supply the service, an Intent to Sole source was posted on Contract Opportunities and yielded no responses. A search in GSA, SBA and VA NAC pharmaceutical yielded that there are some vendors that supply the drugs individually, but they do not have the capacity to mix the drugs as needed for the requirement. CO ordered this type of requirement and know from own personal knowledge that there are no other vendors that could supply this type of Compound Chemotherapy service. Contracting Officer's Certification: Purchase is approved in accordance with FAR13.106-1(b). I certify that the foregoing justification is accurate and complete to the best of my knowledge and belief.

Full description on SAM.gov

Award Overview

Award Number

36C24221A0010

Award Amount (SAM.gov award notice)

$0

Award Date

Nov 20, 2020

Awardee

Original Solicitation

Notice ID: 95bc90eff0454b96b2babcde72d0b955

Posted Date: Nov 23, 2020

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

10
  • 36C24224N0317
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $108.5KSigned Mar 6, 2024
  • 36C24221N0741
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $84.8KSigned Dec 28, 2022
  • 36C24221N0741
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $84.8KSigned Sep 29, 2021
  • 36C24224N0317
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $48.5KSigned May 8, 2024
  • 36C24224N0058
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $40.0KSigned Nov 1, 2023
  • 36C24225N0023
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $25.0KSigned Oct 1, 2024
  • 36C24224N0317
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $21.5KSigned Nov 26, 2024
  • 36C24225N0017
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $20.0KSigned Oct 1, 2024
  • 36C24224N0058
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $2.3KSigned Jan 10, 2025
  • 36C24225N0017
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    —Signed Nov 26, 2025

More From This Vendor

Top 5 most recent

5
  • 36C25621C0027
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $2.1MSigned Jan 30, 2026
  • 36C24225N0023
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    —Signed Jan 9, 2026
  • 36C24225N0017
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    —Signed Nov 26, 2025
  • 36C25621C0027
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $3.3MSigned Jul 25, 2025
  • 36C24224N0058
    OPTUM PHARMACY 601, LLC
    Department of Veterans AffairsNAICS 325412
    $2.3KSigned Jan 10, 2025

Contacts

Documents

No documents available.

Lifecycle

Solicitation:36C24221Q0219
  1. Awarded

This opportunity has been awarded.

  1. Sole Source / J&ACurrentNov 23, 2020

    6505--Contingency for Outsourcing Chemotherapy Compounding drug

    Notice 95bc90eff0454b96b2babcde72d0b955 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

36C24221Q0219

Archive Date

Nov 26, 2020

Office Address

ALBANY, NY, 12208